Pluristem Soars Most in Four Months on Results of Cell Study
Pluristem Therapeutics Inc. (PSTI) surged the most in more than four months after the developer of cell- therapy products said a clinical trial of its PLX-PAD cells to treat critical limb ischemia met all the protocol endpoints.
The shares jumped 11 percent the most since June 20, to 9.92 shekels at 11:41 a.m. in Tel Aviv, giving the Haifa, Israel-based company a market value of 426 million shekels ($116 million).
To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at firstname.lastname@example.org
To contact the editor responsible for this story: Claudia Maedler at email@example.com